Multiple Ascending Dose Study of GLPG0634 in Japanese and Caucasian Healthy Subjects

NCT02162355 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: GLPG0634 50 mg
DRUG: GLPG0634 100 mg
DRUG: GLPG0634 200 mg
DRUG: Placebo

Sponsor

Lakefront Biotherapeutics NV